SIM0278 not checked
Jiangsu Simcere Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Atopic Dermatitis (AD)
- Main trialPhase 2
- “This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult patients (18-75 years) with moderate to severe AD suitable for systemic therapy. Approximately 184 subjects with moderate to severe AD are planned to be randomized in a 1: 1: 1: 1 ratio to SIM0278 low dose, SIM0278 medium dose, SIM0278 high dose, or placebo. Subjects were stratified at randomization by baseline disease severity (moderate \[IGA = 3\] VS severe \[IGA = 4\]). The study consisted of 4 phases: screening, double-blind…”In the company’s words, NCT07175233 on ClinicalTrials.gov
Other drugs for Atopic Dermatitis (AD)
Coming up0
No dates coming up.
Changes2
Last 90 days- 16 NovStatus changed: Not yet recruiting to Active, not recruiting · ClinicalTrials.gov NCT07175233
- 16 NovCompletion date moved: 2026-08-15 to 2026-09-23 · ClinicalTrials.gov NCT07175233
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 23 Sep 2026 | A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis | |
| Phase 1Completed | 18 Mar 2025 | To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026